Search

A recent study conducted by researchers at Washington University School of Medicine in St. Louis has found that psilocybin, the active compound in magic mushrooms, disrupts a critical network of brain areas involved in introspective thinking. This disruption explains the mind-altering effects of the drug and lays the groundwork for the development of psilocybin-based therapies for mental illnesses such as depression and post-traumatic stress disorder. The study provides a roadmap for evaluating the effects of psychoactive drugs on brain function and may accelerate drug development efforts for psychiatric illnesses. However, it is important to note that psilocybin is not approved by the FDA for any medical use, and self-medication with the drug is not recommended. [Extracted from the article]

In a new study researchers report that psilocybin, the active compound in magic mushrooms, temporarily scrambles a critical network of brain areas involved in introspective thinking such as daydreaming and [...]